MIA-606

MIA-606 is a synthetic peptide antagonist of the growth hormone-releasing hormone (GHRH) receptor. It was developed as part of a series of potent GHRH analogs by researchers at the University of Miami and the Veterans Affairs Medical Center, led by Nobel laureate Andrew V. Schally. The compound is designed to inhibit tumor growth by binding to GHRH receptors (GHRHR) expressed on cancer cells, thereby blocking the autocrine and paracrine stimulatory effects of GHRH. In preclinical models of renal cell carcinoma (RCC), MIA-606 has demonstrated significant inhibitory effects on cell proliferation and tumor volume, often by inducing apoptosis and arresting the cell cycle. Its development is primarily focused on oncology, targeting various solid tumors that utilize the GHRH pathway for growth.